Figure 3.
SK-DC vaccine is effective in preventing metastasis. Mice (n = 9) were implanted with 4T1-luc2 cells and tumors were surgically removed at 18 d postimplantation. Test mice were then vaccinated 1 d later via i.p. injection with 1 × 106/100 μL naïve DCs, F/T-treated 4T1 cell-pulsed DCs, or SK-treated 4T1 cell-pulsed DCs (SK-DCs). Two groups of mice were also treated intravenously with 5 mg/kg Dox, but with or without i.p. injection of test DC vaccine, named the Dox and Dox + SK-DCs groups. (A) Bioluminescence imaging of metastatic tumor progression in mice followed. Levels of tumor metastasis in test mice at 40 d post tumor implantation were determined by BLI. The label “D” indicates the mouse died before imaging. The metastasis-free incidence (B) and survival rate (C) of test mice were recorded until 80 d post- tumor implantation. Log-rank test was applied for statistical analyses of survival rate and metastasis-free incidence analysis.